Alvotech SA
ALVO5.260USD
-0.030-0.57%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.64BMarket Cap
22.42P/E TTM
More Details of Alvotech SA Company
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Alvotech SA Info
Ticker SymbolALVO
Company nameAlvotech SA
IPO dateNov 09, 2020
CEOWessman (Robert)
Number of employees1011
Security typeOrdinary Share
Fiscal year-endNov 09
Address9, Rue De Bitbourg
CityLUXEMBOURG
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryLuxembourg
Postal code1273
Phone35244224500
Websitehttps://www.alvotech.com/
Ticker SymbolALVO
IPO dateNov 09, 2020
CEOWessman (Robert)
Company Executives of Alvotech SA
Name
Name/Position
Position
Shareholding
Change
Mr. Richard John Davies
Mr. Richard John Davies
Non-Executive Independent Deputy Chairman of the Board
Non-Executive Independent Deputy Chairman of the Board
1.07M
+1.88%
Ms. Lisa Graver, J.D.
Ms. Lisa Graver, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.16K
+100.00%
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
21.16K
+100.00%
Dr. Linda Mcgoldrick, Ph.D.
Dr. Linda Mcgoldrick, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.16K
+100.00%
Mr. Hjoerleifur Palsson
Mr. Hjoerleifur Palsson
Non-Executive Independent Director
Non-Executive Independent Director
2.35K
--
Mr. Uri Hillel
Mr. Uri Hillel
Chief Quality Officer
Chief Quality Officer
--
--
Mr. Benedikt Stefansson
Mr. Benedikt Stefansson
Director of Investor Relations and Global Communications
Director of Investor Relations and Global Communications
--
--
Ms. Tanya Zharov
Ms. Tanya Zharov
General Counsel
General Counsel
--
--
Mr. Tomas Ekman
Mr. Tomas Ekman
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Joseph E. (Joe) Mcclellan
Mr. Joseph E. (Joe) Mcclellan
Chief Operating Officer
Chief Operating Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Richard John Davies
Mr. Richard John Davies
Non-Executive Independent Deputy Chairman of the Board
Non-Executive Independent Deputy Chairman of the Board
1.07M
+1.88%
Ms. Lisa Graver, J.D.
Ms. Lisa Graver, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.16K
+100.00%
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
21.16K
+100.00%
Dr. Linda Mcgoldrick, Ph.D.
Dr. Linda Mcgoldrick, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.16K
+100.00%
Mr. Hjoerleifur Palsson
Mr. Hjoerleifur Palsson
Non-Executive Independent Director
Non-Executive Independent Director
2.35K
--
Mr. Uri Hillel
Mr. Uri Hillel
Chief Quality Officer
Chief Quality Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2023
FY2022
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
USA
273.04M
55.76%
Europe
157.59M
32.18%
Rest of the world
59.06M
12.06%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Aztiq Pharma Partners SARL
32.45%
Celtic Holdings SCA
28.87%
The Vanguard Group, Inc.
1.39%
Bracebridge Capital, LLC
0.87%
Oaktree Capital Management, L.P.
0.53%
Other
35.89%
Shareholders
Shareholders
Proportion
Aztiq Pharma Partners SARL
32.45%
Celtic Holdings SCA
28.87%
The Vanguard Group, Inc.
1.39%
Bracebridge Capital, LLC
0.87%
Oaktree Capital Management, L.P.
0.53%
Other
35.89%
Shareholder Types
Shareholders
Proportion
Corporation
61.32%
Investment Advisor
2.39%
Investment Advisor/Hedge Fund
1.56%
Hedge Fund
1.33%
Individual Investor
0.44%
Private Equity
0.42%
Research Firm
0.08%
Sovereign Wealth Fund
0.06%
Other
32.39%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
126
18.18M
6.93%
+114.98K
2025Q3
127
18.07M
7.20%
-2.10M
2025Q2
112
20.14M
7.08%
+242.23K
2025Q1
103
19.87M
7.21%
-1.90M
2024Q4
95
18.68M
7.07%
+214.98K
2024Q3
77
17.84M
6.60%
+416.46K
2024Q2
75
16.19M
6.57%
+263.13K
2024Q1
132
15.52M
13.94%
-23.47M
2023Q4
132
18.63M
15.44%
-345.74K
2023Q3
141
19.10M
15.91%
-130.35K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Aztiq Pharma Partners SARL
101.15M
32.46%
-2.59M
-2.49%
Mar 01, 2025
Celtic Holdings SCA
90.01M
28.88%
--
--
Mar 01, 2025
The Vanguard Group, Inc.
4.23M
1.36%
+41.44K
+0.99%
Jun 30, 2025
Bracebridge Capital, LLC
2.71M
0.87%
--
--
Jun 30, 2025
Oaktree Capital Management, L.P.
1.64M
0.53%
-333.90K
-16.92%
Jun 30, 2025
T. Rowe Price International Ltd
1.39M
0.45%
-11.51K
-0.82%
Jun 30, 2025
Littlejohn & Co. LLC
1.32M
0.42%
--
--
Jun 30, 2025
Stefnir hf.
963.47K
0.31%
-10.00K
-1.03%
Aug 31, 2025
Davies (Richard John)
1.07M
0.34%
+19.71K
+1.88%
Mar 01, 2025
PointState Capital LP
1.05M
0.34%
-125.30K
-10.67%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Nasdaq Biotechnology ETF
0.23%
ProShares Ultra Nasdaq Biotechnology
0.19%
iShares Biotechnology ETF
0.07%
Strive Small-Cap ETF
0.03%
Schwab Emerging Markets Equity ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Vanguard ESG International Stock ETF
0%
Vanguard Total World Stock Index Fund
0%
First Trust IPOX Europe Equity Opportunities ETF
0%
Vanguard FTSE All-World ex-US Index Fund
0%
View more
Invesco Nasdaq Biotechnology ETF
Proportion0.23%
ProShares Ultra Nasdaq Biotechnology
Proportion0.19%
iShares Biotechnology ETF
Proportion0.07%
Strive Small-Cap ETF
Proportion0.03%
Schwab Emerging Markets Equity ETF
Proportion0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
Vanguard ESG International Stock ETF
Proportion0%
Vanguard Total World Stock Index Fund
Proportion0%
First Trust IPOX Europe Equity Opportunities ETF
Proportion0%
Vanguard FTSE All-World ex-US Index Fund
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Alvotech SA?
The top five shareholders of Alvotech SA are:
Aztiq Pharma Partners SARL holds 101.15M shares, accounting for 32.46% of the total shares.
Celtic Holdings SCA holds 90.01M shares, accounting for 28.88% of the total shares.
The Vanguard Group, Inc. holds 4.23M shares, accounting for 1.36% of the total shares.
Bracebridge Capital, LLC holds 2.71M shares, accounting for 0.87% of the total shares.
Oaktree Capital Management, L.P. holds 1.64M shares, accounting for 0.53% of the total shares.
Aztiq Pharma Partners SARL holds 101.15M shares, accounting for 32.46% of the total shares.
Celtic Holdings SCA holds 90.01M shares, accounting for 28.88% of the total shares.
The Vanguard Group, Inc. holds 4.23M shares, accounting for 1.36% of the total shares.
Bracebridge Capital, LLC holds 2.71M shares, accounting for 0.87% of the total shares.
Oaktree Capital Management, L.P. holds 1.64M shares, accounting for 0.53% of the total shares.
What are the top three shareholder types of Alvotech SA?
The top three shareholder types of Alvotech SA are:
Aztiq Pharma Partners SARL
Celtic Holdings SCA
The Vanguard Group, Inc.
Aztiq Pharma Partners SARL
Celtic Holdings SCA
The Vanguard Group, Inc.
How many institutions hold shares of Alvotech SA (ALVO)?
As of 2025Q4, 126 institutions hold shares of Alvotech SA, with a combined market value of approximately 18.18M, accounting for 6.93% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.27%.
What is the biggest source of revenue for Alvotech SA?
In FY2024, the -- business generated the highest revenue for Alvotech SA, amounting to -- and accounting for --% of total revenue.
